These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37731485)

  • 21. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease.
    Prescott J; DeBuysscher BL; Feldmann F; Gardner DJ; Haddock E; Martellaro C; Scott D; Feldmann H
    Vaccine; 2015 Jun; 33(24):2823-9. PubMed ID: 25865472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
    Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
    Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.
    Kasereka MC; Mumtaz Z; Hawkes MT
    Drugs Today (Barc); 2021 Jan; 57(1):27-45. PubMed ID: 33594388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A highly effective ferritin-based divalent nanoparticle vaccine shields Syrian hamsters against lethal Nipah virus.
    Yin C; Yao YF; Yang P; Liu H; Gao G; Peng Y; Chen M; Lu M; Zhang X; Guo W; Zhang Z; Hu X; Yuan Z; Shan C
    Front Immunol; 2024; 15():1387811. PubMed ID: 38911870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.
    van Doremalen N; Avanzato VA; Goldin K; Feldmann F; Schulz JE; Haddock E; Okumura A; Lovaglio J; Hanley PW; Cordova K; Saturday G; de Wit E; Lambe T; Gilbert SC; Munster VJ
    NPJ Vaccines; 2022 Dec; 7(1):171. PubMed ID: 36543806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.
    Dahlke C; Kasonta R; Lunemann S; Krähling V; Zinser ME; Biedenkopf N; Fehling SK; Ly ML; Rechtien A; Stubbe HC; Olearo F; Borregaard S; Jambrecina A; Stahl F; Strecker T; Eickmann M; Lütgehetmann M; Spohn M; Schmiedel S; Lohse AW; Becker S; Addo MM;
    EBioMedicine; 2017 May; 19():107-118. PubMed ID: 28434944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.
    Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral immune response in the African green monkey model following Nipah-Malaysia virus exposure by intermediate-size particle aerosol.
    Lara A; Cong Y; Jahrling PB; Mednikov M; Postnikova E; Yu S; Munster V; Holbrook MR
    PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007454. PubMed ID: 31166946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice.
    Li Y; Li R; Wang M; Liu Y; Yin Y; Zai X; Song X; Chen Y; Xu J; Chen W
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32340278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
    Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.
    Mire CE; Geisbert JB; Agans KN; Feng YR; Fenton KA; Bossart KN; Yan L; Chan YP; Broder CC; Geisbert TW
    J Virol; 2014 May; 88(9):4624-31. PubMed ID: 24522928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
    Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
    PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months.
    Pallister JA; Klein R; Arkinstall R; Haining J; Long F; White JR; Payne J; Feng YR; Wang LF; Broder CC; Middleton D
    Virol J; 2013 Jul; 10():237. PubMed ID: 23867060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.